Recent Updates
Recently added Catalysts
REGN

Regeneron to Report Fourth Quarter and Full Year 2012 Financial and Operating Results and Host Conference Call and Webcast on February 14, 2013

Key Takeaway: Regeneron to Report Fourth Quarter and Full Year 2012 Financial and Operating Results and Host Conference Call and Webcast on February 14, 2013

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
2.6%
average across 15 past catalysts
Lead asset
VEGF Trap-Eye
Phase 1 · Diabetic Macular Edema

Full Press Release Details

TARRYTOWN, N.Y.,Jan. 28, 2013/PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)today announced that it will report its fourth quarter and full year 2012 financial and operating results onThursday, February 14, 2013, before the U.S. financial markets open.  The Company will host a conference call and simultaneous webcast at8:30 AM ESTthat day.

Conference Call Information

To access this call, dial (888) 660-6127 (U.S.) or (973) 890-8355 (International).  A link to the webcast may be accessed from the 'Events and Presentations' page of Regeneron's website atwww.regeneron.com.  A replay of the conference call and webcast will be archived on the Company's website and will be available for 30 days.

About Regeneron Pharmaceuticals, Inc.

Regeneron is a leading science-based biopharmaceutical company based inTarrytown, New Yorkthat discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, rheumatoid arthritis, and asthma.  For additional information about the company, please visitwww.regeneron.com.
Contact Information:
Michael Aberman, M.D. Peter Dworkin
Investor Relations Corporate Communications
914-847-7799 914.847.7640
[email protected] [email protected]
Last updated: Jan 28, 2013